Education
About Us
Working with TipRanks
Follow Us
Delta-Fly Pharma, Inc. (JP:4598)
:4598
4598 Stock Chart & Stats
¥507.00
-¥3.00(-0.55%)
At close: 4:00 PM EST
¥507.00
-¥3.00(-0.55%)
Day’s Range― - ―
52-Week Range¥215.00 - ¥793.00
Previous CloseN/A
Volume237.90K
Average Volume (3M)379.72K
Market Cap
¥2.75B
Enterprise Value¥2.31B
Total Cash (Recent Filing)¥730.32M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.62
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-33.68
Shares Outstanding12,159,900
10 Day Avg. Volume693,770
30 Day Avg. Volume379,723
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)18.22
Price to Sales (P/S)0.00
P/FCF Ratio-2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Effectively No DebtAn effectively debt-free balance sheet materially lowers interest and solvency risk for a cash-burning biotech. This structural strength preserves strategic optionality, making it easier to pursue licensing, partnerships or structured financings without immediate pressure from fixed debt service obligations.
Demonstrated Prior Revenue GenerationThe fact the company generated revenue in 2021–2022 shows its programs or arrangements have commercial potential, reducing binary risk compared with purely pre-revenue peers. Structurally, this provides durable optionality for future licensing, partnership monetization, or targeted commercialization efforts if progress resumes.
Lean Operating Footprint (small Headcount)A very small headcount implies a lean cost structure that can stretch available cash and prioritize R&D spend. Over the next several months this structural efficiency can modestly extend runway, lower fixed overhead, and reduce near-term dilution risk if management maintains disciplined cost control.
Bears Say
No Meaningful Revenue And Widening LossesThe sustained absence of meaningful revenue across three years while losses widen to -1.72B in 2025 indicates the company remains pre-commercial and unable to offset operating costs. Structurally this raises the time and capital required to reach self-sustaining profitability and heightens execution risk.
Accelerating Negative Operating Cash FlowOperating cash burn has accelerated materially to -1.83B in 2025 from -940M in 2022, indicating intensifying funding needs. This persistent negative cash generation structurally shortens runway, forces recurrent capital raises, and increases dilution and execution risk for ongoing development programs.
Material Erosion Of Shareholders’ EquityA sharp decline in equity from ~2.08B to ~278M erodes the balance sheet buffer and reduces financial flexibility. Structurally this raises the probability of dilutive financings or asset sales, constrains strategic options, and can increase scrutiny from investors and potential partners on capital allocation and turnaround plans.
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥215.00 and its highest was ¥793.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥2.75B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is May 14, 2026 which is in 86 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on Feb 13, 2026. The company reported -¥33.68 earnings per share for the quarter, missing the consensus estimate of N/A by -¥33.68.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 12,159,900 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥33.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.802%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Technical Analysis
OncoTherapy Science
―
Chiome Bioscience Inc.
―
Oncolys BioPharma, Inc.
―
BrightPath Biotherapeutics Co.Ltd.
―
Kringle Pharma, Inc.
―